| Clinical development is undergoing a structural shift. Protocols are growing more complex, budgets are shrinking, and ...

The AI platform goes through unstructured medical records to surface eligible trials, allowing clinical research teams to ...

In the world of clinical trials, patient recruitment is an ongoing challenge. | In the world of clinical trials, patient ...

The 2022 Option Agreement between Astellas and Taysha has expiredRegaining full rights to TSHA-102 Rett syndrome program enables Taysha to focus ...

In combination with pembrolizumab, for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC). In combination with everolimus, for the treatment of adult patients with ...

Investor event to provide update on pivotal Phase 3 study of IMNN-001 to be held in New York City on November 10, 2025Program will feature ...

Trials-in-progress poster of ongoing pivotal Phase 3 trial of DNA-mediated immunotherapy accepted at both IGCS and ESMO Congress 2025 ...

Ethical and statistical power issues limit the use of randomized controlled trials to study medication and vaccine use during ...

Berry Consultants, LLC announced the release of FACTS 8, the latest version of its industry-leading Fixed and Adaptive Clinical Trial Simulator (FACTS). FACTS 8 is now available to both existing users ...

Ann Kan's role as a senior statistical analyst at NUDACC allows her to blend a skillset that optimally supports multisite ...

Topline results were announced from a phase 3 trial evaluating BNC210 in patients with social anxiety disorder.

Tulisokibart, an investigational anti-TL1A monoclonal antibody currently in Phase 3 trials for ulcerative colitis and Crohn’s disease, to be studied in hidradenitis suppurativa, radiographic axial ...